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Introduction
Upper tract urothelial carcinoma (UTUC) is a very 
uncommon disease that occupies for <5% of all urothelial 
cancers (1). More than 60% of patients with UTUC have 
invasion at diagnosis, whereas only 20% of patients with UC 
of the bladder (UCB) have invasion at diagnosis (2). Invasive 
UTUC has poor prognosis, and as the T stage increases, 
the 5-year survival rate decreases; the median survival of 
patients with T4 disease is about 6 months (3,4). Radical 
nephroureterectomy (RNU) with bladder cuff removal is a 
treatment of choice that can potentially UTUC in patients 
with normal contralateral kidneys, even if conservative 
treatment has a similar survival rate in patients with small 
and low-grade lesions or contraindications to radical surgery 
(4-6). However, in patients with locally advanced UTUC 
who are treated with RNU only, the recurrence rate is 
high (7). Therefore, perioperative chemotherapy may 
reduce the high systemic recurrence rate (8). 
UTUC tumors are relatively sensitive to chemotherapy (9). 
Neoadjuvant chemotherapy (NAC) for UTUC may 
successfully eradicate micro-metastasis and result in 
pathological downstaging. Other reasons for NAC 
preference are cisplatin ineligibility after RNU and 
the chance of delivering higher doses of chemotherapy 
before surgery (3). Meanwhile, there is a potential risk of 
overtreatment without accurate pathological diagnosis. 
This may increase the perioperative morbidity owing to 
chemotherapy (10). However, there is increasing evidence 
that NAC plays an important role in the treatment of 
UTUC (11).
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Several recently published studies have examined 
treatment trends for UTUC using nationwide big data 
(12,13). Browne et al. reported that the National Cancer 
Database displays a rise in chemotherapy for UTUC, 
chiefly in neoadjuvant settings, although NAC continues 
to comprise a small part of the whole chemotherapy (12). 
According to Cohen et al., the SEER-Medicare database 
shows that although NAC remains underused, its use has 
increased during the study period (13).
Proven evidence in bladder cancer
Chemotherapy for UTUC is primarily based on regimens 
that are used for UCB (14,15). NAC for advanced UCB is 
recommended based on level 1 evidence that demonstrated 
a beneficial effect on survival outcomes (16,17). The 
National Comprehensive Cancer Network guidelines 
recommend NAC, followed by radical cystectomy (category 
1 recom mendation) (18). In a Southwest Oncology Group 
randomized trial of 307 patients with muscle-invasive UCB, 
surgery alone was compared with three cycles of NAC 
(methotrexate, vinblastine, doxorubicin, and cisplatin) 
before surgery (19). The study reported that NAC increased 
the median survival among patients with locally advanced 
bladder cancer (77 vs. 46 months, P=0.06) and increased 
the likelihood of eliminating residual cancer (38% vs. 
15%, P<0.001) with no obvious increment in treatment-
related morbidity or mortality. In a meta-analysis of 11 
trials with 3005 patients, cisplatin-based multi-agent NAC 
had a beneficial effect for the 5-year overall survival (OS) 
and disease-free survival (DFS) rates (5% and 9% absolute 
improvement, respectively) (14).
Deterioration of renal function after RNU
While RNU with bladder cuff removal is considered the 
standard treatment for advanced UTUC (4), an alternate 
approach may be needed due to patient comorbidities. 
Depending on tumor stage, grade, and patient factors, 
segmental ureterectomy or even endoscopic management of 
UTUC may be an option.
The majority of patients with UTUC who undergo 
surgery are not eligible for nephrotoxic cisplatin-based 
chemotherapy owing to a decrease in renal function after 
the surgical removal of the diseased kidney, ureter, and 
bladder cuff (10). Kaag et al. determined whether the ability 
to provide chemotherapy before RNU was affected by 
changes in kidney function after surgery (20). They reported 
that a significant decrease in renal function was observed 
after surgery, and these changes likely affected the eligibility 
for adjuvant cisplatin-based therapy. After RNU, renal 
function was significantly diminished, particularly in elderly 
patients. Several studies also reported a significant decrease 
in renal function after surgery (20-23). From this point of 
view, the neoadjuvant use of systemic chemotherapy should 
be strongly considered in advanced UTUC (20).
Experience with renal parenchymal tumors, which has 
proven that the nephron sparing surgery reduces the risk 
of developing chronic kidney disease, can likely apply 
to patients with UTUC (24,25). This concept is very 
important for patients with UTUC because nearly 25% of 
patients have evidence of serious chronic kidney disease at 
diagnosis (26).
Challenges with diagnosis and staging
Diagnosis and staging of UTUC are usually achieved 
by a combination of image modalities, urine cytology, 
endoscopic observation and biopsy of tumor. A CT 
urography is the most commonly used imaging modality 
and the most common abnormal finding is a filling defect 
(27,28). Endoscopic and/or percutaneous biopsies of 
UTUC for pathologic diagnosis, grading, and staging are 
technically difficult and often inaccurate. For this reason, it 
is difficult to develop an optimal treatment plan for UTUC 
patients.
There are several methods being developed to overcome 
the obstacles with clinical staging. One of them is the 
endoscopic luminal ultrasound, which can provide real-
time evaluation of the depth of invasion of tumor. There 
are recent evidence that shows endoluminal ultrasound 
can improve the accuracy of clinical staging at the time of 
flexible ureteroscopy (29).
Pathologic downstaging 
One of the primary rationales for NAC is the possibility of 
pathological downstaging of the tumor (30). In a phase 2 
clinical trial at the MD Anderson Cancer Center, patients 
with locally advanced urothelial cancers were investigated 
for sequential NAC before surgery (31). In five patients 
with NAC followed RNU, three (60%) eventually achieved 
pathologic downstaging to ≤pT1N0 disease. However, 
owing to the small number of patients in this trial, care 
should be taken before drawing conclusions regarding 
the positive effect of NAC in pathologic downstaging of 
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UTUC. Matin et al. also reported that there was significant 
downstaging in the NAC group and that NAC was related to 
a 14% complete remission rate (32). Margulis et al. showed 
that 5 of 41 patients with UTUC who received NAC 
before surgery had no pathologic evidence of cancer (4). 
Moreover, we reported that the NAC group was 4.76 
times more likely to have pathological N phase 0 than the 
surgery-only group in a previous meta-analysis (7).
Improved oncological outcomes
Several meta-analyses suggest the efficacy of NAC in 
patients with UTUC (7,8,10,14,33). We summarize the 
characteristics and outcomes of previous meta-analyses 
in Table 1. The Advanced Bladder Cancer Meta-analysis 
Collaboration showed that a significant survival benefit 
associated with platinum-based chemotherapy for OS (HR 
0.86, 95% CI: 0.77–0.95, P=0.003) and DFS (HR 0.78, 
95% CI: 0.71–0.86, P<0.0001) (14). Leow et al. found a 
cancer-specific survival (CSS) benefit, i.e., a 59% decrease 
in the risk across two retrospective studies evaluating 
NAC (HR 0.41, 95% CI, 0.22–0.76, P=0.005) (10). Yang 
et al. conducted a network meta-analysis to evaluate the 
prognosis of patients with UTUC who received different 
treatments with RNU (33). They reported that compared 
with the control, NAC was associated with a significant 
improvement in CSS. Gregg et al. found that NAC 
exhibited an OS benefit of a 64% decrease in risk across 
two retrospective studies (HR 0.36, 95% CI: 0.19–0.69, 
P=0.002) (8). We evaluated the contemporary role of NAC 
for only patients with locally advanced UTUC (7) and 
showed that NAC increased the survival outcomes of locally 
advanced UTUC (OS, 57%; CSS, 59%; and PFS, 45%). 
Despite the results of these studies, the level of evidence is 
low because few studies were included, and all the included 
studies used retrospective designs.
Future directions
The blockade of the programmed death-ligand 1 (PD-L1) 
–programmed death 1 (PD-1) pathway represents a new 
treatment for cancers with an extensive expression of 
PD-L1 and provides an OS benefit in several cancers 
(34-40). Nevertheless, there remains conflicting evidence 
on the prognostic significance of PD-L1 expression in UC. 
Balar et al. reported that atezolizumab, a blocking antibody 
targeting PD-L1, had a higher response rate in cases of 
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treatment for cisplatin-ineligible patients with progressive 
UC (41). Some studies showed that PD-L1 expression was 
related to poor prognosis in UC (42-45), whereas others did 
not detect a relationship between PD-L1 expression and 
prognosis (46-48). Therefore, further studies are needed to 
improve our comprehension of the prognostic importance 
of PD-L1 expression in UC to better choose patients who 
have a possibility to respond to the blocking agent for 
PD-1/PD-L1.
Conclusions
Our comprehensive review about the role of NAC in 
UTUC revealed that compared with surgery alone, 
NAC may have a beneficial effect on survival outcomes 
in patients with UTUC with a high risk of relapse. It is 
well known that the renal function is deteriorated after 
RNU, and if perioperative chemotherapy is considered 
for advanced UTUC, NAC may be a more reasonable 
option than adjuvant chemotherapy. Several meta-analyses 
demonstrated a beneficial effect of NAC on advanced 
UTUC; however, the level of evidence was relatively 
low; thus, careful interpretation is needed. Moreover, 
careful selection of NAC candidates is needed to avoid the 
possibility of overtreatment. Further trials are needed to 
identify the most suitable patients and validate the use of 
NAC in daily clinical practice. Recent immunotherapy data 
showed positive results for UCB, but there is a lack of data 
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